



## ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong 15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH  
INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH  
INVEST & PARTNERING



## SPEAKER PROFILE

**Brad Walsh**  
**Executive Director**  
**GlyTherix Ltd**

Dr Brad Walsh is Chief Executive Officer and a Director of Minomic International Ltd, a Sydney-based biotechnology company specialising in immuno-oncology.

He founded Minomic to bring to market an innovative biomarker for prostate cancer.

Dr Walsh has led Minomic's scientific and business development, raising A\$26 million and bringing the company to a point at which its first major product, MiCheck®, has progressed through a series of clinical trials in preparation for release to the US market.

A pipeline of potential new therapeutics is in development for prostate, bladder and pancreatic cancer and this has prompted the spin out of a new company, GlyTherix Ltd.

Dr Walsh's career in biotechnology began with a PhD in protein chemistry. Over the following years he led research groups in government agencies, universities and hospitals and was a key part of the establishment of a major national research facility, before forming Minomic in 2007.

He continues to be active in research collaborations and academic supervision and was a joint recipient of one of Australia's most prestigious science awards, a Eureka Prize, for Interdisciplinary Research in 2015. He has co-authored 90 peer reviewed papers and book chapters and six patents.



Name: Brad Walsh  
Position: Executive Director  
Company: GlyTherix Ltd  
Address: Ground Floor, 75 Talavera Road, Macquarie Park NSW 2113  
Website: [glytherix.com](http://glytherix.com)  
Phone: +61 413 231 296  
Email: [brad.walsh@minomic.com](mailto:brad.walsh@minomic.com)